FibroBiologics (FBLG) Set to Announce Earnings on Friday

FibroBiologics (NASDAQ:FBLG) is expected to issue its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect FibroBiologics to announce earnings of ($0.63) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings data on Friday, July 31st. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.27. On average, analysts expect FibroBiologics to post ($3.00) EPS for the current fiscal year and ($3.25) EPS for the next fiscal year.

FibroBiologics Trading Down 0.9%

FBLG stock opened at $0.93 on Wednesday. The company has a market capitalization of $6.20 million, a P/E ratio of -0.18 and a beta of 1.72. FibroBiologics has a twelve month low of $0.62 and a twelve month high of $9.60. The firm has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $2.52.

Wall Street Analysts Forecast Growth

FBLG has been the subject of a number of research reports. Wall Street Zen upgraded FibroBiologics to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. Deutsche Bank Aktiengesellschaft cut FibroBiologics to an “underperform” rating in a research note on Tuesday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, FibroBiologics presently has a consensus rating of “Reduce” and an average price target of $73.00.

About FibroBiologics

FibroBiologics, Inc is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research focuses on fibroblasts, connective-tissue cells that may support tissue repair and influence immune-system activity, as well as biologically active materials derived from these cells.

The company is developing a platform that includes fibroblast-based cell therapies and fibroblast-derived extracellular vesicles. These potential treatments are intended to address conditions involving chronic inflammation, immune dysfunction, and tissue damage.